A daily dose of daraxonrasib combined with chemotherapy shrank tumors in about six in 10 patients with advanced pancreatic cancer in an early clinical trial, according to researchers, Anadolu Agency reported.
The study tested the targeted medicine in 61 patients whose cancer had spread to other organs. None had previously received treatment for metastatic disease. The findings were presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.
According to study sponsor “Revolution Medicines”, 60.7% of patients had a confirmed response, meaning their tumors shrank or became undetectable. Five patients, or 8.2%, had no detectable tumors on scans. Researchers cautioned that this did not mean those patients had been cured.
The disease control rate, which includes patients whose tumors shrank or remained stable, was 90.2%. After a median follow-up of 18.3 months, median progression-free survival was 12.8 months. Progression-free survival measures how long patients live without their cancer worsening.
Researchers caution against drawing conclusions from early results
Researchers stressed that the study was small and had no randomized comparison with chemotherapy alone.
Shivan Sivakumar, a professor and translational oncology specialist at the University of Birmingham, called the results “very encouraging” in comments released by the Science Media Centre. However, he said comparisons with earlier chemotherapy studies could not establish whether the combination extended patients’ lives.
“We do not yet know whether these promising results will translate into longer overall survival,” Sivakumar said.
A larger phase III trial, RASolute 303, is underway. It is comparing daraxonrasib alone and in combination with chemotherapy against chemotherapy alone in patients with previously untreated metastatic pancreatic cancer.
Daraxonrasib targets proteins linked to cancer growth
Daraxonrasib works by blocking active RAS proteins, which transmit signals that drive cancer growth. RAS mutations occur in more than 90% of pancreatic cancers, according to the symposium organizers.
Participants in the early trial took daraxonrasib daily alongside gemcitabine and nab-paclitaxel chemotherapy. Common side effects included rash, diarrhea, fatigue and reduced blood cell counts. About 5% of participants stopped treatment because of side effects attributed to daraxonrasib.
The US Food and Drug Administration approved daraxonrasib, marketed as “Rasonque”, on Aug. 26 for certain adults with metastatic pancreatic adenocarcinoma. The reported approval covers patients who have received at least one previous systemic treatment or cannot receive multidrug systemic therapy.
The first-line combination assessed in the new study remains under investigation.